Longevity & Mitochondrial

FOXO4-DRI

Also known as FOXO4-DRI · FOXO4 D-Retro-Inverso peptide · Proxofim

PreliminarySubcutaneousIntravenousNot FDA-approved; research use only, not approved or established for human administration

FOXO4-DRI is a synthetic D-retro-inverso peptide engineered to disrupt the interaction between the FOXO4 protein and the tumor suppressor p53. In senescent cells, FOXO4 is thought to keep p53 in the nucleus and prevent cell death; blocking this interaction is proposed to release p53 to trigger apoptosis, selectively eliminating senescent cells. The evidence is entirely preclinical, based on cell and mouse studies. Because it acts on p53, a critical tumor-suppressor protein, its safety in humans is unknown.

Studied / used for

Studied for selective clearance of senescent cells (senolytic activity)
Researched for vascular and endothelial aging in animal models
Studied for tissue function in aged mice
Researched in the context of the FOXO4-p53 interaction

Commonly reported side effects

Human safety data not available
Theoretical risks from targeting p53 signaling
Side effect profile uncharacterized in humans

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds